BioCentury
ARTICLE | Finance

Alize's assets

How Alize Pharma is using an asset-centric model to maximize capital efficiency

March 23, 2015 7:00 AM UTC

French biotech Alize Pharma S.A.S. is employing an asset-centric model similar to those used by Atlas Venture or Index Ventures to maximize both capital efficiency and the attractiveness of the assets in its pipeline to potential partners.

Last week, the company announced that Alize Pharma III S.A.S., a newco established last year to develop osteoporosis peptide I-HBD1, raised €1.8 million ($1.9 million) in seed financing. Investors included Sofimac, Octalfa S.A.S., Sham, Rhone Alpes Création, Crédit AgrÃcole Création, CEMA Inc. and TAB Consulting, which is the holding company of the Alize Pharma companies. ...